» Articles » PMID: 31373491

Aspartate Residues Far from the Active Site Drive O-GlcNAc Transferase Substrate Selection

Overview
Journal J Am Chem Soc
Specialty Chemistry
Date 2019 Aug 3
PMID 31373491
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

O-GlcNAc is an abundant post-translational modification found on nuclear and cytoplasmic proteins in all metazoans. This modification regulates a wide variety of cellular processes, and elevated O-GlcNAc levels have been implicated in cancer progression. A single essential enzyme, O-GlcNAc transferase (OGT), is responsible for all nucleocytoplasmic O-GlcNAcylation. Understanding how this enzyme chooses its substrates is critical for understanding, and potentially manipulating, its functions. Here we use protein microarray technology and proteome-wide glycosylation profiling to show that conserved aspartate residues in the tetratricopeptide repeat (TPR) lumen of OGT drive substrate selection. Changing these residues to alanines alters substrate selectivity and unexpectedly increases rates of protein glycosylation. Our findings support a model where sites of glycosylation for many OGT substrates are determined by TPR domain contacts to substrate side chains five to fifteen residues C-terminal to the glycosite. In addition to guiding design of inhibitors that target OGT's TPR domain, this information will inform efforts to engineer substrates to explore biological functions.

Citing Articles

Photoactivatable O-GlcNAc Transferase Library Enables Covalent Chemical Capture of Solvent-Exposed TPR Domain Interactions.

Joiner C, Glogowski T, NewRingeisen E, Huynh H, Roberts M, Rognerud M Chembiochem. 2024; 26(1):e202400709.

PMID: 39541256 PMC: 11729469. DOI: 10.1002/cbic.202400709.


The roles of OGT and its mechanisms in cancer.

Liu X, Wang J, Xiang Y, Wang K, Yan D, Tong Y Cell Biosci. 2024; 14(1):121.

PMID: 39285476 PMC: 11406787. DOI: 10.1186/s13578-024-01301-w.


O-linked β-N-acetylglucosamine (O-GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy.

Qi B, Chen Y, Chai S, Lu X, Kang L Diabet Med. 2024; 42(2):e15436.

PMID: 39279604 PMC: 11733667. DOI: 10.1111/dme.15436.


Identification of a Polypeptide Inhibitor of -GlcNAc Transferase with Picomolar Affinity.

Hammel F, Payne N, Marando V, Mazitschek R, Walker S J Am Chem Soc. 2024; 146(38):26320-26330.

PMID: 39276112 PMC: 11440498. DOI: 10.1021/jacs.4c08656.


The non-catalytic domains of O-GlcNAc cycling enzymes present new opportunities for function-specific control.

Hu C, Wang K, Jiang J Curr Opin Chem Biol. 2024; 81:102476.

PMID: 38861851 PMC: 11323188. DOI: 10.1016/j.cbpa.2024.102476.


References
1.
Hornbeck P, Zhang B, Murray B, Kornhauser J, Latham V, Skrzypek E . PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2014; 43(Database issue):D512-20. PMC: 4383998. DOI: 10.1093/nar/gku1267. View

2.
Rafie K, Raimi O, Ferenbach A, Borodkin V, Kapuria V, van Aalten D . Recognition of a glycosylation substrate by the O-GlcNAc transferase TPR repeats. Open Biol. 2017; 7(6). PMC: 5493779. DOI: 10.1098/rsob.170078. View

3.
Leavy T, Bertozzi C . A high-throughput assay for O-GlcNAc transferase detects primary sequence preferences in peptide substrates. Bioorg Med Chem Lett. 2007; 17(14):3851-4. PMC: 3225185. DOI: 10.1016/j.bmcl.2007.05.008. View

4.
Lazarus M, Nam Y, Jiang J, Sliz P, Walker S . Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature. 2011; 469(7331):564-7. PMC: 3064491. DOI: 10.1038/nature09638. View

5.
Ortiz-Meoz R, Merbl Y, Kirschner M, Walker S . Microarray discovery of new OGT substrates: the medulloblastoma oncogene OTX2 is O-GlcNAcylated. J Am Chem Soc. 2014; 136(13):4845-8. PMC: 3988687. DOI: 10.1021/ja500451w. View